Figure 1. Study design for EP- and FP-type receptor inhibitor experiments. Each well was seeded with 30,000 HMGECs and allowed to differentiate for 48 h (see Methods). HMGECs were pre-treated with receptor inhibitors for 30 min before the introduction of latanoprost 50 µg/ml for 3 h. Receptor inhibition was maintained throughout the three-hour incubation with latanoprost. Following incubation, cell viability was assayed with the Cell Titer-Glo Luminescent Cell Viability Assay (see Methods). There were nine replicates per condition, which included SC51322 (EP1 inhibitor), PF-04418948 (EP2 inhibitor), L-798,106 (EP3 inhibitor), ONO-AE3–208 (EP4 inhibitor), and AL 8810 (FP inhibitor).